Leerink Partners' Ominous Sign on MannKind (MNKD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Piper Jaffray Maintains Underweight on MannKind (MNKD) Following Results and Grim Outlook
November 10, 2015 7:01 AM ESTPiper Jaffray analyst Joshua Schimmer reiterated an Underweight rating and $1.50 price target on MannKind (NASDAQ: MNKD) following results.
Schimmer commented, "While cost-cutting measures will help curtail the cash burn, the disappointing launch of Afrezza and increasing net-debt position seem to be making the... More
MannKind (MNKD) Misses Q3 EPS by 1c
November 9, 2015 10:18 AM ESTMannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).
For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insulin therapy, were $4.1 million and $17.1 million, respectively, which we recorded as deferred product... More
